EUVIMEDEUVIMED entdecken
Crossref

Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era

Yumiko Toda, Masahiro Ashizawa, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Chihiro Yamamoto, Kaoru Hatano und 4 weitere

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03752-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Yumiko Toda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Urate Oxidase, Leukemia, Myeloid, Acute, Allopurinol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy. In patients without TLS at diagnosis of AML, the risk for developing TLS was classified as high in 44 patients, intermediate in 41 and low in 57, according to the current guidelines. Allopurinol alone was administered to prevent hyperuricemia in all patients. All three patients who developed CTLS after diagnosis of AML were at high risk of TLS, and had elevated serum creatinine levels and a WBC count greater than 200,000 per microliter at diagnosis of AML. Allopurinol may be insufficient to prevent TLS in high-risk patients with renal dysfunction at diagnosis of AML, especially those with a high tumor burden and a WBC count of 200,000 or more, which indicates that prophylactic administration of rasburicase should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Lysis SyndromeUrate OxidaseLeukemia, Myeloid, AcuteAllopurinolHumansMaleFemaleMiddle AgedAgedAdultInduction ChemotherapyAged, 80 and overHyperuricemiaAdolescentIncidenceYoung Adult

Stichwörter der Autor:innen

Acute myeloid leukemiaAllopurinolRasburicaseTLSTumor lysis syndrome

Substanzen

rasburicaseUrate OxidaseAllopurinol

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan. ycanda-tky@umin.ac.jp.

Zitieren

APA

Toda, Y., Ashizawa, M., Murahashi, R., Nakashima, H., Ikeda, T., Kawaguchi, S. I., Nagayama, T., Umino, K., Minakata, D., Morita, K., Yamamoto, C., Hatano, K., Sato, K., Fujiwara, S. I., Ohmine, K., & Kanda, Y. (2024). Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03752-w

Vancouver

Toda Y, Ashizawa M, Murahashi R, Nakashima H, Ikeda T, Kawaguchi SI, et al. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03752-w

BibTeX
@article{Toda2024,
  author = {Toda, Yumiko and Ashizawa, Masahiro and Murahashi, Rui and Nakashima, Hirotomo and Ikeda, Takashi and Kawaguchi, Shin-Ichiro and Nagayama, Takashi and Umino, Kento and Minakata, Daisuke and Morita, Kaoru and Yamamoto, Chihiro and Hatano, Kaoru and Sato, Kazuya and Fujiwara, Shin-Ichiro and Ohmine, Ken and Kanda, Yoshinobu},
  title = {Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03752-w}
}
Kostenlos starten →